tirzepatide day one Can you take every 5 days? What the pharmacology actually says I’m excited to finally lose

Newly released survey data revealed the following key trends for GLP-1 drug coverage: 51% of employers provide coverage for diabetes only (a decrease from 56% in 2025 and 66% in 2024) 37% provide coverage for both diabetes and weight loss (on the rise from 31% in 2025 and 17% in 2024) 12% cover GLP-1 drugs for other conditions (sleep apnea, cardiovascular disease, etc.)

Limited evidence from research in men with type 2 diabetes and obesity suggests that weight loss and improved metabolic control associated with GLP-1 agonist therapy may correlate with improvements in erectile function and sexual satisfaction

But as this study shows, they are most effective when combined with coaching, tracking, and lifestyle support

Daewoong Pharmaceutical has added a once-monthly semaglutide injection to an obesity pipeline that already includes oral drugs and microneedle patches, giving the Korean drugmaker three shots at a market increasingly defined by how easily patients can stay on treatment